drugset / Trial / NCT00528905

Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia

NCT00528905

Phase 2 Completed 400 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.

Timeline

Start
2007-08
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ispronicline Small molecule Oral

Indications